There has been a significant increase in marketing authorisa-tion approvals of anticancer drugs in the EU. We performed an analysis over the period 2010-2017 to investigate which factors impact the approval time of anti-cancer products and compared this to data from a similar analysis by Hartmann et al covering 2006-2011.
read the full abstract here
